The Food and Drug Administration (FDA) sent another warning to drug giant Novo Nordisk over an advertisement for weight loss drug Ozempic, saying the ad contains false and misleading claims.

In a letter dated Feb. 26, the FDA said the video contains misbranding of Ozempic, which in turn makes distributing the drug in violation of federal law.

“The video includes claims and presentations that misrepresent the efficacy of Ozempic,” the letter states, citing specific claims contained in the consumer advertisement including one that says “for adults with type 2 diabetes, Ozempic is the GLP-1 with the most FDA-approved uses.”

The statement, according to the agency, is “misleading because it implies that all patients with type 2 diabetes are candidates for all the FDA-approved indications for Ozempic, when this is not the case without the presence of concurrent disease states.”

“Patients with type 2 diabetes must have the concurrent disease state of ‘established cardiovascular disease’ or ‘chronic kidney disease’ to be candidates” of certain uses of the drug, it said.

GLP-1 drugs are a type of medication found in Ozempic, Wegovy, and Zepbound that can mimic a natural stomach hormone used to regulate a person’s blood sugar, slow digestion, and suppress appetite. The drug is primarily used to treat type 2 diabetes and for weight loss.

The FDA’s letter also chided the Danish drug giant for misrepresenting Ozempic’s approved uses in the ad and implying that the drug was superior to other GLP‑1 medicines for treating type 2 ‌diabetes.

Regulators ​added that the ad’s comedic elements, including a scene comparing Ozempic to other ​GLP‑1s, created the impression that competing drugs lacked ​meaningful benefits.

“Novo Nordisk received ​an ‘Untitled Letter’ from the FDA ​concerning ‌an advertising campaign for Ozempic,” confirmed Novo Nordisk spokesperson Liz Skrbkova to media outlets this week. “We take all regulatory feedback seriously and are in the process of responding to ‌the FDA to address their concerns regarding the advertisement’s presentation.”

It’s not the first time the FDA has warned Novo Nordisk about alleged false claims in ads. In September, the drug regulator faulted the company for an advertisement for Ozempic and Wegovy, among other drugs, for what it said were misleading statements about the medications.

The company got another warning letter from the FDA on Feb. 6 about a Wegovy advertisement the agency said was false or misleading.

That ad, the letter stated, misleadingly implied “benefits beyond physical weight loss such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific condition, when this has also not been demonstrated.”

The FDA warnings come after the Trump administration issued a memorandum last year saying that the FDA would move to make sure that regulations around drug advertising are enforced to make sure “transparency and accuracy” is being provided.

For the past several years, both Democratic and Republican lawmakers have pressed the FDA to take action against pharmaceutical company advertisements, particularly those that are deployed through social media.

The Epoch Times contacted Novo Nordisk for comment Wednesday.

Reuters contributed to this report.